Pfizer (PFE) Reaffirms FY 2026 Outlook Amid Leadership Change

With an annual dividend yield of 6.96%, Pfizer Inc. (NYSE:PFE) is included among the 12 Best S&P 500 Stocks to Buy for Dividends.

Pfizer (PFE) Reaffirms FY 2026 Outlook Amid Leadership Change

Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company’s global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer health care products.

Pfizer Inc. (NYSE:PFE) announced on June 18 that its CFO, Dave Denton, will step down from his current role and leave the company on August 15 to pursue an opportunity in the consumer goods sector. He will be replaced by Cecile Guegan as Interim CFO, effective August 16, while the pharma giant conducts a comprehensive internal and external search.

At the same time, Pfizer Inc. (NYSE:PFE) also reaffirmed its outlook for FY 2026. It continues to target total company revenues in the range of $59.5 billion to $62.5 billion and adjusted diluted earnings in the range of $2.80 to $3 per share for the year. The guidance assumes adjusted gross margins in the mid-70s range, in addition to cost discipline and investment.

With a robust annual dividend yield of 6.96%, Pfizer Inc. (NYSE:PFE) was also recently included in our list of the 12 High Yield Fortune 500 Stocks to Buy Now.

While we acknowledge the risk and potential of PFE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PFE and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Most Profitable American Stocks to Buy in 2026 and 14 Best S&P 500 Stocks to Buy Now According to Analysts

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1